Antithrombin

From Wikipedia, the free encyclopedia


Antithrombin dimer drawn from PDB 1E03.
serpin peptidase inhibitor, clade C (antithrombin), member 1
Identifiers
Symbol	SERPINC1 AT3
HUGO	775
Entrez	462
OMIM	107300
RefSeq	NM_000488
UniProt	P01008
Other data
EC number	1E03
Locus	Chr. 1 q23-q25.1

Antithrombin is a small protein molecule that inactivates several enzymes of the coagulation system. It is a glycoprotein produced by the liver and consists of 432 amino acids. It contains three disulfide bonds and a total of four possible glycosylation sites. α-antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin.^[1]

1 Structure
2 Function
3 Role in disease
4 Genetics
5 Nomenclature
6 References
7 External links

[edit] Structure

Antithrombin has a half life in blood plasma of around 3 days.^[2] The normal antithrombin concentration in human blood plasma is approximately 0.12 mg/ml, which is equivalent to a molar concentration of 2.3 μM.^[3] Antithrombin has been isolated from the plasma of a large number of species additional to humans.^[4] As deduced from protein and cDNA sequencing, cow, sheep, rabbit and mouse antithrombins are all 433 amino acids in length, which is one amino acid longer than human antithrombin. The extra amino acid is thought to occur at amino acid position 6. Cow, sheep, rabbit, mouse and human antithrombins share between 84 and 89% amino acid sequence identity.^[5] They all have four potential N-glycosylation sites. These occur at asparagine (Asn) amino acid numbers 96, 135, 155 and 192 in humans and at similar amino acid numbers in other species. All these sites are occupied by covalently attached oligosaccharide side chains in the predominant form of human antithrombin, α-antithrombin. The potential glycosylation site at asparagine 135 is not ocupied in a minor form of antithrombin, β-antithrombin.^[6] Shown below are the location of the four potential glycosylation sites within the tertiary structure of an antithrombin monomer, as taken from the protein data bank file 2ANT. In this structure only Asn 155 is glycosylated by the addition of a single N-acetyl glucosamine residue.

[edit] Function

Antithrombin is a serpin (serine protease inhibitor). The physiological target proteases of antithrombin are those of the intrinsic coagulation system, namely the activated forms of Factor X (Xa), Factor IX (IXa), Factor VII (VIIa), Factor XI (XIa), Factor XII (XIIa) and Factor II (thrombin) (IIa). Protease inactivation results as a consequence of the trapping the protease in an equimolar complex with antithrombin in which the active site of the protease enzyme is inaccessible to its usual substrate.^[5] The formation of an antithrombin-protease complex involves an interaction between the protease and a specific reactive peptide bond within antithrombin. In human antithrombin this bond is between arginine (arg) 393 and serine (ser) 394.^[5] As shown below the reactive arg 393 - ser 394 bond is located on an exposed loop at the surface of the molecule. This loop is termed the reactive site loop.

It is thought the trapping of protease enzymes in inactive antithrombin-protease complexes results as a consequence of their attack of the reactive bond. Where the attack of a similar bond within their normal substrate results in its rapid proteolytic cleavage, on initiating an attack on the antithrombin reactive bond the antithrombin inhibitor is activated to trap the enzyme at an intermediate stage during the proteolytic process. Given time thrombin is able to cleave the reactive bond within antithrombin and an inactive thrombin-antithrombin complex will dissociate, however the time it takes for this to occur may be greater than 3 days.^[7]

The rate of antithrombins inhibition of protease activity is greatly enhanced by its additional binding to heparin.

[edit] Role in disease

Antithrombin deficiency is a rare hereditary disorder that generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.

[edit] Genetics

The gene for antithrombin is located on the first chromosome, locus 1q23-q25.1.

[edit] Nomenclature

Antithrombin is officially called antithrombin III and is a member of a larger family of antithrombins (numbered I, II etc. to VI). All are serpins. Only AT III (and possibly AT I) is medically significant, with AT III generally referred to as antithrombin.

[edit] References

^ Bjork, I; Olson, JE (1997). Antithrombin, A bloody important serpin (in Chemistry and Biology of Serpins). Plenum Press, 17-33. ISBN 0-306-45698-2.
^ Collen DJ, Schetz F. et al. (1977). "Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration". Eur. J. Clin. Invest 7: 27-35. PMID 65284.
^ Conrad J, Brosstad M. et al. (1983). "Molar antithrombin concentration in normal human plasma". Haemostasis 13: 363-368. PMID 6667903.
^ Jordan RE. (1983). "Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism". Arch. Biochem. Biophys 227: 587-595. PMID 6607710.
^ ^a ^b ^c Olson ST, Bjork I. (1994). "Regulation of thrombin activity by antithrombin and heparin". Sem. Thromb. Hemost. 20 (4): 373-409. PMID 7899869.
^ Brennan SO, George PM, Jordan, RE. (1987). "Physiological variant of antithrombin-III lacks carbohydrate side chain at Asn 135". FEBS Lett 219: 431-436. PMID 3609301.
^ Danielsson A and Bjork, I (1980). "Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor". FEBS Lett 119: 241-244. PMID 7428936.